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tions, health care utilization, and costs in 12-month follow-up period were as-
sessed. Complications included microvascular (e.g. diabetic retinopathy), macro-
vascular (e.g. atherosclerosis), and other diabetic complications. Cox proportional
hazards models were used to compare complication rates, adjusting for baseline
characteristics. Generalized linearmodels/two-partmodelswere similarly used for
utilizations and costs. RESULTS: The study included 15,139 patients (47.0% female;
mean age 52.6 [SD8.1]) receiving DPP4i combinations and 41,602 patients (42.4%
female; mean age 51.9 [SD8.3]) receiving SU combinations. At baseline, DPP4i
patients had higher rates ofmedication use than SU patients (MET: 61.7% vs. 40.4%;
TZD: 23.0% vs. 11.8%; lipid-lowering: 53.2% vs. 35.4%; number of different medica-
tions: 7.2 [SD5.1] vs. 5.3 [SD4.9], respectively; all P0.0001). After adjustment,
hazard ratios of complications were significantly lower for patients treated with
DPP4i combinations (microvascular complications: 0.872, P0.0001;macrovascular
complications: 0.933, P0.0015; other complications: 0.921, P0.0001). DPP4i pa-
tients also had lower adjusted diabetes-related utilization incidence rate ratios
(hospitalization: 0.76; ER visits: 0.69; outpatient visits: 0.87; all P0.0001). DPP4i
patients incurred higher mean diabetes-related prescription drug costs ($1,629 vs.
$476, P0.0001) but lower all-cause medical services costs ($6731 vs. $7251,
P0.0001). CONCLUSIONS: Compared to SU combinations, DPP4i combinations are
associated with lower rates of diabetic complications and health care utilization.
While patients onDPP4i combination incur higher diabetes-related drug costs, they
were found to have lower all-cause medical-services costs.
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OBJECTIVES: The prevalence of diabetes in China is rising, and was recently esti-
mated as 9.7% in The China National Diabetes andMetabolic Disorders Study, with
a large proportion of patients previously undiagnosed. The costs of treating com-
plications in all patients and managing the disease in diagnosed patients are high.
The aim of this study was to estimate the annual cost of illness for all patients and
lifetime diabetes costs for diagnosed patients in China. METHODS: A model was
developed to estimate the cost of diabetes for 2011. Diabetes complication costs
were derived from hospital surveys in Beijing and Chengdu. Diabetes treatment
strategies were based on the intensive arm of the UK Prospective Diabetes Study
(UKPDS). The annual incidence and prevalence rates for major diabetic complica-
tions, including cardiovascular, renal, ocular, foot ulcer, neuropathy and treat-
ment-related events, were derived from international studies of diagnosed pa-
tients with baseline disease duration of less than ten years, including the UKPDS.
All patients were at risk of incurring complication costs, and only diagnosed pa-
tients could incur treatment and management costs. For diagnosed patients life-
time cost projections were made, discounted by 3% annually, using a validated
diabetes model. RESULTS: The 2011 cost of diabetes was estimated as CNY 13,326
per diagnosed and CNY 4,727 per undiagnosed patient, with the difference attrib-
utable to diabetes treatment and management costs. Based on a total population
approaching 1.4 billion and previously reported disease prevalence rates, the na-
tional cost of diabetes in 2011 was estimated as CNY 1,214 billion. In diagnosed
patients, a lifetime cost of CNY 301,716 per patient was estimated (or CNY 18,253
billion nationally); diabetes complications comprised 53% of total costs.
CONCLUSIONS: The costs of diabetes in China are high. Based on a Gross Domestic
Product (GDP) of CNY 47,156.4 billion for 2011, appropriate care for every diabetic in
China would cost 2.6% of GDP.
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OBJECTIVES: Data from the 2006 Malaysian National Health Morbidity Survey
showed that the overall prevalence of diabetes in Malaysia is over 11%. The high
prevalence of diabetes and themanagement of diabetes-related complications has
considerable implications in terms of health care spending, with 16% of overall
health care spending inMalaysia attributed to themanagement of diabetes in 2010.
The objective of the study was to estimate current direct costs associated with
diabetes-related complications in Malaysia.METHODS:Most direct costs of diabe-
tes complications were derived from interviews with three key opinion leaders in
the field of diabetes in Malaysia. Dialysis costs were sourced from published liter-
ature.Mean costswere then estimated calculated for first and subsequent years for
each event/complication. All costs are presented in 2011 Malaysian Ringgits (MYR)
(converted to US dollars [USD], exchange rate USD 1 to MYR 3.14). RESULTS: End-
stage renal disease was associated with the highest annual per patient costs, with
mean first year costs for hemodialysis and peritoneal dialysis being MYR23,500
(USD7,070) and MYR36,000 (USD11,465) per year, respectively. Costs of renal trans-
plant were MYR26,000 (USD8,280) in the year of transplant andMYR3,000 (USD955)
per year in subsequent years. Other complications associatedwith high direct costs
were amputation and prosthesis (MYR425 andMYR3,750, respectively [USD135 and
USD1,194, respectively]), cataract operation (MYR3,221, USD1,026) and myocardial
infarction (MYR1,233 [USD393] in year of event and MYR367 [USD117] per year in
subsequent years). Additionally, neuropathy was associated with mean costs of
MYR900 (USD287) in the first year and MYR675 (USD215) per year thereafter.
CONCLUSIONS: Diabetes is associated with a substantial economic burden in Ma-
laysia, and themanagement of diabetes related complications is likely to represent
a significant proportion of the overall costs. The cost data reported in this study
represents a useful resource for future economic evaluations of diabetes in Malay-
sia.
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OBJECTIVES: Indonesia has the fourth highest number of cases of diabetesmellitus
in the world. Estimates from 2010 indicated that approximately 7,000,000 people in
Indonesia had diabetes. Although diabetes-related complications are associated
with a considerable economic burden, there is a paucity of data on the costs of
diabetes in Indonesia. The aim of the present studywas to estimate the direct costs
associatedwithmanaging diabetes-related complications from a health care payer
perspective in Indonesia. METHODS: Literature review of EMBASE, PubMed, the
Cochrane Library and grey literature provided few publications to inform cost es-
timates. Costs were evaluated based on interviews with local expert physicians
and were collected for the first year of treatment and each subsequent year per
event/complication. Costs were classified into six main groups: cardiovascular
complications, renal complications, acute events, eye-disease, neuropathy and di-
abetic foot complications, and concomitant medications. Costs were expressed in
2011 Indonesian Rupiah (IDR) with US dollar (USD) conversions (exchange rate
USD1 to IRD8,940). RESULTS:Myocardial infarction was the most costly cardiovas-
cular complication with a first year cost of IDR202.7 million (USD22,673), followed
by stroke, unstable angina and heart failure. Renal complications were also signif-
icant contributors of cost with transplantation estimated to cost approximately
IDR192.5 million (USD21,532) in the first year and IDR45 million (USD5,033) in each
subsequent year. Hemodialysis cost over IDR89.3 million (USD9,994) annually and
peritoneal dialysis cost over IDR57.1million (USD6,391) each year. Themost expen-
sive ocular procedure was cataract surgery (IDR5.1 million [USD573]). Lower limb
amputation was themost costly of the diabetic foot complications (IDR21.2million
[USD2,375]). CONCLUSIONS: Estimates of complication costs suggest that the 7
million patients with diabetes represent a substantial economic burden in Indone-
sia. The data collected in this study represent a valuable resource to investigate the
economic impact of diabetes treatments in the Indonesian setting.
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OBJECTIVES: Diabetes is associated with a substantial and growing clinical and
economic burden in India, accounting for approximately 11% of national health
care expenditure in 2010. Moreover, the management of diabetes-related compli-
cations is the main contributor to the overall cost of the disease. The objective of
the study was to obtain current direct costs for the management of diabetes-re-
lated complications in India.METHODS: Direct costs of diabetes-related complica-
tions were derived from interviews with three expert diabetologists based in India,
with the exception of the costs of renal procedures, which were derived from
published, country-specific literature. Mean values based on all experts’ estimates
were calculated for first and subsequent years for each complication. Costs were
classified into 6 groups (management, cardiovascular complications, renal-compli-
cations, acute-events, eye-disease and neuropathy/foot ulcers). Costs are pre-
sented in 2011 Indian Rupees (INR) with equivalent US dollar (USD) values (ex-
change rate USD1 to INR50.23). RESULTS: At an individual patient level the most
expensive diabetes-related complication was end-stage renal disease, where both
peritoneal dialysis and hemodialysis were associated with direct annual costs of
INR788,059 and INR755,223, respectively, and renal transplant was associated with
costs of INR577,910 (USD11,505) in the year of transplant and INR295,522 (USD5,883)
in each subsequent year. The direct cost of cardiovascular complications was also
high; for examplemyocardial infarction cost approximately INR162,500 (USD3,235)
in the year of event and INR16,500 (USD328) in subsequent years. Gangrene
(INR55,000 [USD1,095] per event) and infect ulcer (INR27,500 [USD547] per event)
had the highest costs of the diabetic foot complications. CONCLUSIONS: In India,
direct costs associated with themanagement of diabetes-related complications, in
particular renal and cardiovascular complications, contribute significantly to the
economic burden associated with diabetes. Costs presented in this study will pro-
vide useful data for economic evaluations of diabetes interventions in India.
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OBJECTIVES: To estimate the direct medical cost for diabetes mellitus (DM) related
complications in China. METHODS: Data were obtained from a cross-sectional
survey of 20 internists of endocrine and metabolism departments in 20 hospitals
from September to November in 2011 in 9 cities of China. 11 internists worked in
tier 3 hospitals and 9 worked in tier 2 hospitals. All the internists who are depart-
ment director or deputy director were asked to give the average costs of complica-
tions treatment according to their clinical practice and retrospective medical re-
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cords. The diabetes related complications considered in this study were classified
into chronic complications (Cardiovascular disease, Cerebrovascular disease, Neu-
ropathy, Retinopathy, Nephropathy, Peripheral vascular diseases and foot damage)
and acute complications (Ketoacidosis and major hypoglycemic). The direct med-
ical costs were reported as annual costs including hospitalization, daily medica-
tions and examinations for DM-related chronic complications and as event costs
for DM-related acute ones. All costs were reported in 2011 US dollar using the
exchange rate of 6.47 Chinese Yuan to 1 USD. RESULTS: The annual medical cost
for DM related complications per patient with and without hospitalizations: Myo-
cardial infarction $6248.32 and $2025.26; Angina $4707.12 and $1453.63; Congestive
Heart Failure $3433.08 and $1009.18; Stroke $3214.74 and $1401.46; Peripheral vas-
cular disease $3348.11 and $1301.34; Neuropathy $2226.86 and $854.38. Renal fail-
ure with Haemodialysis $11245.93 and Peritoneal dialysis $7802.03; Renal trans-
plant $33772.50 with operation and $8934.27 for daily maintenance. The event cost
for Retinopathy: Laser operation $296.79; Cataract operation $1313.56; Amputation
$2072.22; Infected ulcer treatment: $3007.11; Ketoacidosis $1493.55; Major hypogly-
cemic $729.18. CONCLUSIONS: Themedical costs for DM related complications are
overwhelming compared with the costs of insulin and hypoglycemic agents espe-
cially for those diabetic patients with severe nephropathy. Considering the high
prevalence of diabetes and its complications diabetes poses substantial economic
burden to the whole society in China.
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OBJECTIVES: The primary objective of this study was to estimate the cost effec-
tiveness of treating diabetic foot ulcers with ANGIPARS™ plus good wound care
(GWC) compared with GWC alone in Iranian health care settings. A secondary
objective was to analyse the effect of different treatment practices on the econom-
ics of caring for diabetic foot ulcers.METHODS: A 6-month Markov computer sim-
ulation model was used to assess the cost effectiveness in Iran of treating diabetic
foot ulcers with ANGIPARS™ plus GWC versus GWC alone. Transition probabilities
were taken from a prospective study of 20 patients and ANGIPARS™ efficacy was
based on 20-week healing rates in a recentmeta-analysis of clinical trials involving
50 patients. Country-specific treatment cost data were collected in collaboration
with local economic consultations and combined with the disease model to esti-
mate the incremental cost per ulcer-free month gained. The model was then run
using hypothetical low- and high-intensity resource usage profiles to investigate
the economics of caring for diabetic foot ulcers. RESULTS: Over the course of
6-month, individuals who received ANGIPARS™ plus GWC were, on average, pre-
dicted to spend an additional 0.81 months (24% longer) free of ulcers and to expe-
rience a 9% lower risk of undergoing a lower extremity amputation than individu-
als who received GWC alone. Consequently, ANGIPARS™ plus GWCwas estimated
to be net cost saving in Iran. CONCLUSIONS: ANGIPARS™ may be a cost-effective
treatment for neuropathic diabetic foot ulcers in a wide range of Iranian settings.
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OBJECTIVES: The diabetic peripheral neuropathy (DPN) is the most common dia-
betic patients’ complicationwhich is accompaniedwith substantial economic bur-
den regarding the productivity loss andmedical therapy. In this studywe analyzed
the cost effectiveness of pregabalin for treatment of diabetic neuropathic pain in
Iran. METHODS: To evaluate the efficacy of pregabalin we designed a systematic
review of published articles by searching on PubMed, Scopus and Google scholar.
Our keywords were: “pregabalin”, “neuropathic pain”, “diabetic peripheral neurop-
athy”, etc. The pain score was the outcome of interest for evaluation of the treat-
ment efficacy in peripheral neuropathic pain. For calculation of cost we only con-
sider direct cost of treatment. RESULTS:Out of 8994, finally 5 articleswere included
in the studywhichmet our inclusion criteria. All of these reportswere Randomized
Clinical Trial (RCT) of the comparison of pregabalin with placebo. Considering the
efficacy extracted from the reports, pregabalin 75 mg/day and 150 mg/day didn’t
have any significant efficacy in comparison with placebo thus the ICER for other
treatment doses was calculated. In pregabalin 300 mg/day the ICER for domestic
produced generic pregabalin was 0.27 dollar per day per pain score reduction and
for imported Lyrica was 2.74 dollar per day per pain score reduction. The results for
pregabalin 600 mg/day were 0.62 and 4.37 respectively. CONCLUSIONS: Our anal-
ysis indicated pregabalin 300 mg/day and 600 mg/day as cost effective treatments.
About the inclusion of pregabalin into insurance positive list if the prescribers
prefer to order pregabalin once a day (As we learned from the expert opinion)
therefore only 300 mg and 600 mg dosage forms are eligible for including into the
positive list.
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OBJECTIVES: To assess medical literature for an overview of the cost-effectiveness
of second-line treatment strategies to achieve different target levels of HbA1c in
subgroups of type 2 diabetes patients.METHODS: Studies are being retrieved from
Pubmed, Cochrane and HEED databases using relevant search strategies. Pre-spec-
ified inclusion/exclusion criteria will identify study types, such as randomized
controlled trials (RCTs), observational and retrospective studies assessing the role
of HbA1c targets in glycaemic control of type 2 diabetes patients. The outcomes of
interest are HbA1c, blood glucose levels, treatment, hypoglycaemia, adherence to
therapy and economic and clinical consequences of therapy. Two researchers are
independently extracting the data from included studies. Clinical data from RCTs
will be analysed using RevMan (5). RESULTS: Though there have been several trials
assessing glycaemic control in type 2 diabetes in the last few years, the wealth of
new evidence is useful but confusing and conflicting. This study will probably
provide the much-needed evidence for glycaemic goal in different groups of type 2
diabetes patients. The study hopes to demonstrate whether there would be glycae-
mia-independent differences in HbA1c between ethnic groups and the evidence of
time dependency of HbA1c. CONCLUSIONS: The data from published studies will
hopefully answer some of the prevailing uncertainties regardingHbA1c targets and
inform policy makers and health professionals about the existing evidence in the
treatment of type 2 diabetes.
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OBJECTIVES: Over a decade ago, Briggs and O’Brien declared the ‘death’ of cost-
minimisation analysis (CMA). The principle of CMA, however, as described by
Drummond is still being considered valid by regulators such as the Australian
Pharmaceutical Benefits Advisory Committee (PBAC), which recommends which
drugs should be reimbursed under the Pharmaceutical Benefits Schedule (PBS).
This study sought to examine the evidence needed for drug reimbursement in
Australia for diabetes drugs when presenting a CMA. METHODS: Current PBAC
guidelines were reviewed specifically from a cost minimisation point of view. Pub-
lic summary documents (which summarise PBAC deliberations) for all reimburse-
ment decisions related to diabetes drugs over the past 5 years were extracted. Data
pertaining to clinical claims, economic analyses and decision were analysed.
RESULTS: Public summary documents were reviewed for eight diabetes drugs:
insulin glulisine, insulin detemir, liraglutide pioglitazone, rosiglitazone, saxaglip-
tin, sitagliptin, vildagliptin. Of these, five reimbursement submissions were based
on CMAs, two on cost effectiveness analyses (CEA) and one on both. The CMA
submissions demonstrated non-inferioritywhen compared to the nominated com-
parator either by presenting head-to-head clinical trial evidence, adjusted indirect
comparisons or pooled individual patient data (IPD) analyses. All were recom-
mended for reimbursement in Australia. Notably, budget impact of each was lim-
ited (AU$10 million over a 5-year period). The three CEA submissions claimed
superiority of their products over the nominated comparators either in terms of
efficacy or safety but none were successful. Notably, each was associated with a
considerable budget impact. CONCLUSIONS: Far from being dead, CMA remains
alive and well in Australia. The PBAC accepts CMAs on the basis of non-inferiority
and perhaps also if reimbursement is associated with a limited budget impact.
Acceptable evidence is not restricted to head-to-head trials, but also includes ad-
justed indirect comparisons as well as IPD pooled from multiple clinical trials.
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OBJECTIVES: To evaluate the long-term cost-utility of liraglutide versus
glimepiride as add-on therapy tometformin in patientswith Type 2 diabetes, based
on the results of clinical trial conducted in Asian population. METHODS: The val-
idated UKPDS Outcomes Model was used to project life expectancy, quality ad-
justed life years (QALYs), incidence of diabetes-related complication and cost of
complications in patients receiving those regimens. Baseline cohort characteristics
and treatment effects were derived from an Asian study. China-specific complica-
tion costs and utility scoreswere taken from local studies. Patients’ outcomeswere
modelled for 30 years and incremental cost-effectiveness ratios (ICERs) were cal-
culated for liraglutide compared with glimepiride from the health care system
perspective. Both costs and clinical benefits were discounted at 3%. Sensitivity
analyses were also performed. RESULTS: Over a period of 30 years, compared with
glimepiride, liraglutide 1.8mg was associated with improvements in life expec-
tancy (0.1 year) and QALY (0.168), and a reduced incidence of diabetes-related
complications leading to an ICER per QALY gained of CNY 256871. Sensitivity anal-
yses indicated that the final ICER was highly sensitive to time horizon, price of
liraglutide and the effects of liraglutide in improving the systolic blood pressure
and lipid profiles but insensitive to the effect of liraglutide in the reduction in
HbA1c. CONCLUSIONS: Long-term projections indicated that liraglutide was asso-
ciated with increased life expectancy, QALYs, and reduced incidences of compli-
cation comparing with glimepiride. If the 3X per capita GDP was adopted as the
WTP threshold per QALY, however, the administration of liraglutide was not con-
sidered cost-effective in China, and less likely to be cost effective in most Asian
developing economies (e.g., Thailand, Malaysia) than Asian developed economies
(Japan, Singapore). But with a 38% reduction of our modelled acquisition cost of
liraglutide (from CNY369.2 - CNY 228.02), liraglutide could be considered cost-ef-
fective in China.
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